SK285088B6 - Spôsob kryštalizácie hydrochloridu 1-[2-(naft-2-yl)etyl]-4(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropiridínu, zmes formy I a formy III hydrochloridu 1-[2-(naft-2-yl)etyl]-4(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropiridínu a farmaceutický prostriedok obsahujúci túto látku - Google Patents

Spôsob kryštalizácie hydrochloridu 1-[2-(naft-2-yl)etyl]-4(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropiridínu, zmes formy I a formy III hydrochloridu 1-[2-(naft-2-yl)etyl]-4(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropiridínu a farmaceutický prostriedok obsahujúci túto látku Download PDF

Info

Publication number
SK285088B6
SK285088B6 SK828-99A SK82899A SK285088B6 SK 285088 B6 SK285088 B6 SK 285088B6 SK 82899 A SK82899 A SK 82899A SK 285088 B6 SK285088 B6 SK 285088B6
Authority
SK
Slovakia
Prior art keywords
ethyl
trifluoromethylphenyl
mixture
naphth
form iii
Prior art date
Application number
SK828-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK82899A3 (en
Inventor
Antoine Caron
Bruno Franc
Olivier Monnier
Original Assignee
Sanofi - Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi - Aventis filed Critical Sanofi - Aventis
Publication of SK82899A3 publication Critical patent/SK82899A3/sk
Publication of SK285088B6 publication Critical patent/SK285088B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK828-99A 1996-12-23 1997-12-23 Spôsob kryštalizácie hydrochloridu 1-[2-(naft-2-yl)etyl]-4(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropiridínu, zmes formy I a formy III hydrochloridu 1-[2-(naft-2-yl)etyl]-4(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropiridínu a farmaceutický prostriedok obsahujúci túto látku SK285088B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9615904A FR2757543B1 (fr) 1996-12-23 1996-12-23 Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues
PCT/FR1997/002393 WO1998028271A1 (fr) 1996-12-23 1997-12-23 Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Publications (2)

Publication Number Publication Date
SK82899A3 SK82899A3 (en) 1999-12-10
SK285088B6 true SK285088B6 (sk) 2006-06-01

Family

ID=9499043

Family Applications (1)

Application Number Title Priority Date Filing Date
SK828-99A SK285088B6 (sk) 1996-12-23 1997-12-23 Spôsob kryštalizácie hydrochloridu 1-[2-(naft-2-yl)etyl]-4(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropiridínu, zmes formy I a formy III hydrochloridu 1-[2-(naft-2-yl)etyl]-4(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropiridínu a farmaceutický prostriedok obsahujúci túto látku

Country Status (39)

Country Link
EP (1) EP0950050B1 (ru)
JP (2) JP4499188B2 (ru)
KR (1) KR100586670B1 (ru)
CN (1) CN1129580C (ru)
AR (1) AR009672A1 (ru)
AT (1) ATE307802T1 (ru)
AU (1) AU736697B2 (ru)
BR (1) BR9714081A (ru)
CA (1) CA2275596C (ru)
CO (1) CO5070688A1 (ru)
CZ (1) CZ296689B6 (ru)
DE (1) DE69734460T2 (ru)
DK (1) DK0950050T3 (ru)
DZ (1) DZ2383A1 (ru)
EE (1) EE04188B1 (ru)
EG (1) EG21567A (ru)
ES (1) ES2251038T3 (ru)
FR (1) FR2757543B1 (ru)
HK (1) HK1024002A1 (ru)
HR (1) HRP970699B1 (ru)
HU (1) HU227425B1 (ru)
IL (1) IL129938A (ru)
IN (1) IN186976B (ru)
IS (1) IS2357B (ru)
MY (1) MY118015A (ru)
NO (1) NO312364B1 (ru)
NZ (1) NZ336130A (ru)
PL (1) PL190494B1 (ru)
RS (1) RS49882B (ru)
RU (1) RU2192416C2 (ru)
SA (1) SA98180971B1 (ru)
SI (1) SI0950050T1 (ru)
SK (1) SK285088B6 (ru)
TR (1) TR199901363T2 (ru)
TW (1) TW518322B (ru)
UA (1) UA60324C2 (ru)
UY (1) UY24825A1 (ru)
WO (1) WO1998028271A1 (ru)
ZA (1) ZA9711576B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues
FR2782082B3 (fr) * 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
WO2011111857A1 (ja) 2010-03-12 2011-09-15 株式会社日本触媒 吸水性樹脂の製造方法
ES2604405T3 (es) * 2011-04-15 2017-03-06 Emcure Pharmaceuticals Limited Un procedimiento para rilpivirina mejorado

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Also Published As

Publication number Publication date
HK1024002A1 (en) 2000-09-29
PL190494B1 (pl) 2005-12-30
SI0950050T1 (sl) 2006-04-30
KR20000069504A (ko) 2000-11-25
HUP0001387A2 (hu) 2000-09-28
MY118015A (en) 2004-08-30
NO993076D0 (no) 1999-06-22
RS49882B (sr) 2008-08-07
DE69734460T2 (de) 2006-07-06
ES2251038T3 (es) 2006-04-16
EP0950050A1 (fr) 1999-10-20
ATE307802T1 (de) 2005-11-15
FR2757543B1 (fr) 1999-04-02
KR100586670B1 (ko) 2006-06-07
TR199901363T2 (xx) 1999-08-23
HRP970699B1 (en) 2007-03-31
FR2757543A1 (fr) 1998-06-26
PL334256A1 (en) 2000-02-14
UY24825A1 (es) 1998-04-21
IS5076A (is) 1999-06-10
IN186976B (ru) 2001-12-22
DZ2383A1 (fr) 2002-12-28
CN1241180A (zh) 2000-01-12
HU227425B1 (en) 2011-05-30
HUP0001387A3 (en) 2002-03-28
HRP970699A2 (en) 1998-10-31
EP0950050B1 (fr) 2005-10-26
NO993076L (no) 1999-06-22
DK0950050T3 (da) 2006-01-23
BR9714081A (pt) 2000-05-09
CZ296689B6 (cs) 2006-05-17
JP2001507012A (ja) 2001-05-29
CO5070688A1 (es) 2001-08-28
IS2357B (is) 2008-04-15
ZA9711576B (en) 1998-06-25
SK82899A3 (en) 1999-12-10
UA60324C2 (ru) 2003-10-15
TW518322B (en) 2003-01-21
CZ229299A3 (cs) 1999-09-15
JP4499188B2 (ja) 2010-07-07
AU736697B2 (en) 2001-08-02
CN1129580C (zh) 2003-12-03
WO1998028271A1 (fr) 1998-07-02
JP2009197022A (ja) 2009-09-03
RU2192416C2 (ru) 2002-11-10
CA2275596A1 (en) 1998-07-02
YU28999A (sh) 2003-01-31
EE9900264A (et) 2000-02-15
NO312364B1 (no) 2002-04-29
EG21567A (en) 2001-12-31
DE69734460D1 (de) 2005-12-01
CA2275596C (en) 2005-10-11
EE04188B1 (et) 2003-12-15
AR009672A1 (es) 2000-04-26
IL129938A (en) 2004-06-20
SA98180971B1 (ar) 2006-09-13
AU5668498A (en) 1998-07-17
IL129938A0 (en) 2000-02-29
NZ336130A (en) 2001-01-26

Similar Documents

Publication Publication Date Title
US20020016351A1 (en) New crystals of celecoxib
EP1505066A1 (en) Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic
SK285088B6 (sk) Spôsob kryštalizácie hydrochloridu 1-[2-(naft-2-yl)etyl]-4(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropiridínu, zmes formy I a formy III hydrochloridu 1-[2-(naft-2-yl)etyl]-4(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropiridínu a farmaceutický prostriedok obsahujúci túto látku
WO1984000033A1 (en) 1,4-dihydro-pyridine derivatives, preparation thereof and pharmaceutical compositions containing them
WO2006090263A1 (en) Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions
US6489334B2 (en) Method for the crystallization of a tetrahydropyridin derivative and resulting crystalline forms
US20020193386A1 (en) Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof
MXPA01012328A (es) Polimorfos de un citrato de (2-benzhidril- 1-azabiciclo(2.2.2) oct-3-il- (5-iso- propil-2- metoxibencil) -amina como antagonistas del receptor de nk-1.
SK280555B6 (sk) Kryštalické monohydráty hydrochloridu endo-2,3-dih
SK283917B6 (sk) Mikročasticová forma tetrahydropyridínového derivátu a farmaceutický prostriedok obsahujúci túto mikročasticovú formu
MXPA99005620A (en) Method for the crystallisation of a tetrahydopyridin derivative and resulting crystalline forms
US6310250B1 (en) Form A of fluoxetine hydrochloride
US20030191141A1 (en) Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof
US20030191140A1 (en) Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof
WO2006093041A1 (ja) Ｎ－ベンジル－ｎ－エチル－２－（７－メチル－８－オキソ－２－フェニル－７,８－ジヒドロ－９ｈ－プリン－９－イル）アセトアミドの新規結晶
WO2003042161A1 (en) Venlafaxine hydrochloride polymorphs
EP2206701A1 (en) Crystalline form of flupirtine ((2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl)-carbamic acid ethyl ester)
BG106692A (bg) Твърди форми на 5-[ [ 6-[ (2-флуорофенил)метокси]- 2-нафталенил]метил] -2, 4- тиазолидиндион
CZ20003722A3 (cs) Maleat paroxetinu
MXPA99005621A (en) Micro-particulate form of a tetrahydropyridin derivative
MXPA00009884A (en) Paroxetine maleate
WO2000034245A2 (en) Crystalline form of benzoquinoline-3-one derivatve as inhibitor of 5-alpha reductase

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20111223